Results for flutikasoonfuroaadi translation from Estonian to English

flutikasoonfuroaadi monoteraapia
fluticasone furoate monotherapy

flutikasoonfuroaadi seonduvus plasmavalkudega on üle 99 %.
the plasma protein binding of fluticasone furoate is greater than 99 %.

flutikasoonfuroaadi/vilanterooli üleannustamise spetsiifiline ravi puudub.
there is no specific treatment for an overdose with fluticasone furoate/vilanterol.

jaotumine: flutikasoonfuroaadi seonduvus plasmavalkudega on üle 99 %.
distribution: the plasma protein binding of fluticasone furoate is greater than 99 %.

flutikasoonfuroaadi ninasprei on ette nähtud ainult nasaalseks manustamiseks.
fluticasone furoate nasal spray is for administration by the intranasal route only.

nendel patsientidel on tõenäoline flutikasoonfuroaadi ekspositsiooni edasine suurenemine.
the exposure of fluticasone furoate is likely to be further increased in such patients.

puuduvad andmed intranasaalse flutikasoonfuroaadi kasutamise kohta maksakahjustusega patsientidel.
there are no data with intranasal fluticasone furoate in patients with hepatic impairment.

flutikasoonfuroaadi täpne toimemehhanism astma ja koki sümptomite korral on teadmata.
the precise mechanism through which fluticasone furoate affects asthma and copd symptoms is not known.

flutikasoonfuroaadi manustamisel kombinatsioonis vilanterooliga ei täheldatud olulisi uusi toksilisuse ilminguid.
administration of fluticasone furoate combined with vilanterol did not result in any significant new toxicity.

alla 12-aastastel patsientidel ei ole flutikasoonfuroaadi/vilanterooli farmakokineetikat uuritud.
the pharmacokinetics of fluticasone furoate/vilanterol in patients less than 12 years of age has not been studied.

flutikasoonfuroaadi ja vilanterooli puhul kõige sagedamini kirjeldatud kõrvaltoimed olid peavalu ja nasofarüngiit.
the most commonly reported adverse reactions with fluticasone furoate and vilanterol were headache and nasopharyngitis.

seetõttu ei ole läbi viidud kliinilisi uuringuid, et hinnata flutikasoonfuroaadi koostoimeid teiste ravimitega.
therefore, no clinical studies have been conducted to investigate interactions of fluticasone furoate on other drugs.

flutikasoonfuroaadi või vilanterooltrifenataadi ja/või metaboliitide rinnapiima eritumise kohta ei ole piisavalt andmeid.
there is insufficient information on the excretion of fluticasone furoate or vilanterol trifenatate and/or metabolites in human milk.

puudusid tõendid flutikasoonfuroaadi määratava sisalduse suurema esinemissageduse kohta eakatel patsientidel nooremate patsientidega võrreldes.
there was no evidence for a higher incidence of patients with quantifiable fluticasone furoate concentrations in the elderly, when compared with the younger patients.

sesoonse ja aastaringse allergilise riniidi korral kasutatud flutikasoonfuroaadi ohutuse ja efektiivsuse uuringutes sai ravi üle 2700 patsiendi.
there were over 2700 patients treated with fluticasone furoate in safety and efficacy studies for seasonal and perennial allergic rhinitis.

flutikasoonfuroaat läbib ulatusliku esmase maksapassaaži, mistõttu suureneb raske maksahaigusega patsientidel tõenäoliselt intranasaalse flutikasoonfuroaadi süsteemne ekspositsioon.
fluticasone furoate undergoes extensive first-pass metabolism, therefore the systemic exposure of intranasal fluticasone furoate in patients with severe liver disease is likely to be increased.

flutikasoonfuroaadi manustamist rinnaga toitvatele naistele tuleb kaaluda vaid juhul, kui oodatav kasu emale on suurem võimalikust ohust lapsele.
administration of fluticasone furoate to women who are breastfeeding should only be considered if the expected benefit to the mother is greater than any possible risk to the child.

flutikasoonfuroaadi/vilanterooli manustamist rasedale tuleks kaaluda vaid juhul, kui oodatav kasu emale ületab võimalikud ohud lootele.
administration of fluticasone furoate/vilanterol to pregnant women should only be considered if the expected benefit to the mother is greater than any possible risk to the foetus.

mõlema uurigu kombineeritud analüüs näitas kopsufunktsiooni kliiniliselt märkimisväärset paranemist flutikasoonfuroaadi/vilanterooli 92/22 mikrogrammi kasutamisel.
in an integrated analysis of both studies, fluticasone furoate/vilanterol 92/22 micrograms showed clinically meaningful improvements in lung function.

eliminatsioon: suukaudse ja intravenoosse manustamise järgselt toimus eliminatsioon peamiselt fekaalsel teel, mis näitab flutikasoonfuroaadi ja tema metaboliitide eritumist sapiga.
elimination: elimination was primarily via the faecal route following oral and intravenous administration indicative of excretion of fluticasone furoate and its metabolites via the bile.